Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT04324164
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Sponsor: Hunan Province Tumor Hospital
View on ClinicalTrials.gov
Summary
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Official title: Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
800
Start Date
2020-03-24
Completion Date
2027-12-24
Last Updated
2025-01-27
Healthy Volunteers
No
Conditions
Interventions
DRUG
Third-generation EGFR-TKI
Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.
DRUG
EGFR-TKI
All EGFR-TKI
Locations (1)
Yongchang Zhang
Changsha, Hunan, China